Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/8/2014
Start Date:December 2011
End Date:July 2023
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy

This study will examine specific biomarkers in primary invasive breast cancer and explore
their correlation with patient outcome following standard neoadjuvant treatment.


Inclusion Criteria:

- The patient has 18 years of age or older at the time of consent.

- The patient has provided pre-treatment tumor samples for WT1 expression screening and
gene expression profiling in the context of the NCT01220128 study.

- The patient has a histologically or cytologically confirmed primary invasive breast
cancer.

- The patient has provided written informed consent before any new information or new
material is provided to the Sponsor.

- The patient is planned to receive, is receiving or has received standard and/or
investigational therapy for breast cancer.

- The patient is planned to receive, is receiving or has received standard and/or
investigational therapy for breast cancer.

Exclusion Criteria:

Not applicable.
We found this trial at
4
sites
Amarillo, Texas 79106
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Charleston, South Carolina 29425
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Newark, Delaware 19713
?
mi
from
Newark, DE
Click here to add this to my saved trials
Plantation, Florida 33324
?
mi
from
Plantation, FL
Click here to add this to my saved trials